- Cedres, Nira
- Ferreira, Daniel
- Nemy, Milan
- Machado, Alejandra
- Pereira, Joana B.
- Shams, Sara
- Wahlund, Lars-Olof
- Zettergren, Anna
- Stepankova, Olga
- Vyslouzilova, Lenka
- Eriksdotter, Maria
- Teipel, Stefan J.
- Grothe, Michel J.
- Blennow, Kaj
- Zetterberg, Henrik
- Schöll, Michael
- Kern, Silke
- Skoog, Ingmar
- Westman, Eric
[Background and Objectives] Several pathologic processes might contribute to the degeneration of the cholinergic system in aging. We aimed to determine the contribution of amyloid, tau, and cerebrovascular biomarkers toward the degeneration of cholinergic white matter (WM) projections in cognitively unimpaired individuals., [Methods] The contribution of amyloid and tau pathology was assessed through CSF levels of the Aβ42/40 ratio and phosphorylated tau (p-tau). CSF Aβ38 levels were also measured. Cerebrovascular pathology was assessed using automatic segmentations of WM lesions (WMLs) on MRI. Cholinergic WM projections (i.e., cingulum and external capsule pathways) were modeled using tractography based on diffusion tensor imaging data. Sex and APOE ε4 carriership were also included in the analysis as variables of interest., [Results] We included 203 cognitively unimpaired individuals from the H70 Gothenburg Birth Cohort Studies (all individuals aged 70 years, 51% female). WM lesion burden was the most important contributor to the degeneration of both cholinergic pathways (increase in mean square error [IncMSE] = 98.8% in the external capsule pathway and IncMSE = 93.3% in the cingulum pathway). Levels of Aβ38 and p-tau also contributed to cholinergic WM degeneration, especially in the external capsule pathway (IncMSE = 28.4% and IncMSE = 23.4%, respectively). The Aβ42/40 ratio did not contribute notably to the models (IncMSE<3.0%). APOE ε4 carriers showed poorer integrity in the cingulum pathway (IncMSE = 21.33%). Women showed poorer integrity of the external capsule pathway (IncMSE = 21.55%), which was independent of amyloid status as reflected by the nonsignificant differences in integrity when comparing amyloid-positive vs amyloid-negative women participants (T201 = −1.55; p = 0.123)., [Discussion] In cognitively unimpaired older individuals, WMLs play a central role in the degeneration of cholinergic pathways. Our findings highlight the importance of WM lesion burden in the elderly population, which should be considered in the development of prevention programs for neurodegeneration and cognitive impairment., This research was supported by the Swedish Research Council (2012-5041, 2013-8717, 2015-02830, 2016-02282, 2016-02282, 2020-02014, and 2021-01861), the Swedish Research Council for Health, Working Life and Welfare (2013-1202, AGECAP 2013-2300, 2013-2496, and 2013-0475), the Swedish Foundation for Strategic Research (SSF, RB13-0192), the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro), the Swedish State under the agreement between the Swedish government and the county councils, the ALF agreement (FoUI-954893 and FoUI-962240), the Center for Medical Innovation (CIMED, FoUI-954459 and FoUUI-20200505), the Swedish Alzheimer Foundation (AF-967495, AF-939687, and AF-968032), the Swedish Brain Foundation (FO2020-0150, FO2021-0119, and FO2022-0175), Stonhes Stiftelse, Stiftelsen för Gamla Tjänarinnor, Demensförbundet, Neurofonden, Lindhés Advokatbyrå AB, Eivind och Elsa K: son Sylvans Stiftelse, Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond, Funding for Geriatric diseases at Karolinska Institutet, Research funding at Karolinska Institutet, Fundacion Canaria Dr. Manuel Morales, and the Czech Alzheimer Foundation. MJG is supported by the “Miguel Servet” program [CP19/00031] and a research grant [PI20/00613] of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). J.B. Pereira is supported by grants from the Swedish Research Council (2018-02201), the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro Startup Grant), The Center for Medical Innovation (20200695), Gamla Tjänarinnor (2019-00803), Demensforbundet, Stonhes, and a Senior Researcher faculty position from Karolinska Institutet. H. Zetterberg is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018–02532), the European Research Council (#681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, and ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. S. Kern was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALF GBG-81392 and ALF GBG-771071), the Alzheimerfonden (AF-842471, AF-737641, and AF-939825), and the Swedish Research Council (2019-02075) Stiftelsen Demensfonden, Stiftelsen Hjalmar Svenssons Forskningsfond, Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond., Peer reviewed